TABLE 5.
The effect of CHM intervention on the incidence of specific adverse events.
| Outcome or subgroup | Studies | Patients | Heterogeneity | Effect measure | Or (95% CI) | p | |
|---|---|---|---|---|---|---|---|
| p | I2/% | ||||||
| CHM Alone vs CWM | |||||||
| Perimenopausal Symptoms | 3 (Ding and Shi, 2012; Zhang, 2012; Dou, 2015) | 186 | 0.98 | 0 | Odds Ratio | 0.09 [0.02, 0.50] | 0.004 |
| Androgenic Response | 1 (Ding and Shi, 2012) | 56 | - | - | Odds Ratio | 0.14 [0.01, 2.80] | 0.31 |
| Hepatic Function Impairment | 2 (Ding and Shi, 2012; Zhang, 2012) | 116 | 0.92 | 0 | Odds Ratio | 0.11 [0.01, 0.94] | 0.04 |
| CHM + CWM vs CWM | |||||||
| Perimenopausal Symptoms | 8 (Chen, 2015; Du, 2015; Han, 2016; Xing, 2016; Zhou, 2016; Hu and Y, 2018; Qiu and Wan, 2019; Liu, 2020) | 632 | 0.73 | 0 | Odds Ratio | 0.36 [0.21, 0.61] | 0.0001 |
| Androgenic Response | 3 (Zhou and Liu, 2013; Du, 2015; Zhou, 2016) | 346 | 0.81 | 0 | Odds Ratio | 0.58 [0.20, 1.65] | 0.31 |
| Hepatic Function Impairment | 4 (Zhou and Liu, 2013; Chen, 2015; Xing, 2016; Liu, 2020) | 308 | 0.41 | 0 | Odds Ratio | 0.39 [0.17, 0.92] | 0.03 |
| Gastrointestinal Discomfort | 5 (Zhou and Liu, 2013; Du, 2015; Zhou, 2016; Hu and Y, 2018; Qiu and Wan, 2019) | 504 | 0.99 | 0 | Odds Ratio | 0.75 [0.36, 1.58] | 0.45 |
| Physical Pain | 3 (Du, 2015; Hu and Y, 2018; Qiu and Wan, 2019) | 278 | 0.87 | 0 | Odds Ratio | 0.63 [0.16, 2.45] | 0.50 |
| Allergic Reactions | 2 (Du, 2015; Hu and Y, 2018) | 210 | 0.93 | 0 | Odds Ratio | 0.37 [0.08, 1.63] | 0.19 |
Abbreviation: CHM: chinese herbal medicine; CWM: conventional western medicine.